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Dear Editor,
Bloodstream infections (BSI) caused by Enterobacteriaceae 
strains are of great concern in clinical settings. Furthermore, 
the presence of extended-spectrum β-lactamases (ESBLs) 
in these microorganisms has added potential difficulties in 
treating these infections. 
Quantitative pharmacodynamics (PD) parameters have been 
proposed to evaluate clinical and microbiological outcomes.1 
Changes in minimum inhibitory concentration (MIC) and 
pharmacokinetics (PK) parameters affect these PD ratios. 
Currently, a great concern is how to optimize antimicrobial 
use due to a restricted number of new antimicrobial drugs 
against Gram-negative rods. The evaluation of the PK/PD 
relationship has received great consideration because it has 
led to optimization of dosage regimens and improvement of 
outcomes.2
Currently, limited human studies are available on the 
relevance of PK/PD parameters in terms of outcome for 
complicated bacteremia caused by Gram-negative rods. 
With this study, we sought to assess the risk factors 
associated with 14- and 28-day mortality, and the adequacy of 
beta-lactam therapy in a group of patients with bloodstream 
infection (BSI) caused by Enterobacteriaceae. Moreover, a 
mathematical PD model was utilized to evaluate whether 
a lack of ideal PD goal impact on mortality rates. 
A retrospective cohort study was performed in a university-
affiliated hospital (Hospital São Paulo) in São Paulo, Brazil. Adult 
patients were eligible if they had a documented nosocomial 
bloodstream infection caused by an Enterobacteriaceae strain, 
were treated with beta-lactam antibiotics for at least 72 h 
by the attending physician, and had a creatinine clearance 
≥ 30 mL/min. Immunocompromised patients were excluded. 
Briefly,  immunocompromised patients were those 
on  chemotherapy ,  those  who were  neutropenic 
(ANC < 500 cells/mm3), and those with AIDS. Infection was 
defined by the CDC criteria. We analyzed only the first 
episode of bacteremia from each patient. Data collected 
from patients’ medical records included demographic 
characteristics, comorbidities, antimicrobial treatment, 
presence of ESBL, presence of septic shock, delay in starting 
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adequate antimicrobial therapy, achievement of PD goal, and 
in-hospital mortality. Delay to start adequate antimicrobial 
therapy was defined as the therapy starting > 48h after 
collection of blood culture.
A mathematical PD model was employed. Briefly, 
MICs were determined using the automated BD Phoenix. 
% T > MIC was estimated mathematically based on the 
equation % T > MIC = ln[Dose* f/Vd*MIC)]*[V/Cl]*[100/DI], 
where V is the volume of distribution in liters at steady state, 
DI is the dosing interval (h), ln is the natural logarithm, f is the 
fraction of unbound drug, and Cl is the total body clearance 
in liters per hour.3 V and Cl were taken from published 
population pharmacokinetic studies.4-6 For cephalosporins 
and carbapenens, %T > MIC of free drug at 50% and 40% 
of the dosing interval were the PD targets, respectively.7
The first microorganism obtained from each patient’s 
bloodstream was used for all microbiologic assessments. 
Identification and MICs were determined for each isolate by 
automated BD Phoenix.
Categorical  variables were compared using the 
chi-square test, and continuous variables were compared 
by Student’s t-test. A p-value < 0.1 was considered to be 
statistically significant. To determine independent predictors 
of mortality, logistic regression analysis was performed. 
Variables considered for model inclusion were adjusted 
by age and comorbidities. A p-value < 0.05 was considered 
to be statistically significant in multivariate analyses. All 
calculations were computed using MedCalc, version 11.6, 
Mariakerke, Belgium.
During the study period, 76 adult patients with 
bacteremia caused by Enterobacteriaceae who received 
≥ 72 h of β-lactam therapy were identified. Twelve patients 
were excluded because they were immunocompromised, 
thus 64 patients were evaluated. 40 patients were male 
(62.5%), and the median age was 64 years. The 14- and 
28-day mortality rates were 25% (16/64) and 35.9% (23/64), 
respectively. The most common microorganisms isolated 
were Klebsiella pneumoniae (39; 60.9%) and Proteus mirabilis 
(14; 21.8%). 30 patients (46.8%) had ESBL-positive strains. 
Imipenem was the most utilized antimicrobial drug 
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(31/64, 48.4%) followed by cefepime (23/64, 35.9%). The 
MIC50/90 for cefepime, imipenem and piperacillin/tazobactam 
were > 16/> 16, 1/1, > 64/> 64 and > 16/> 16, 4/4, ≤ 4/> 64 for 
Klebsiella pneumonia and Proteus mirabilis, respectively. Only 
15 (23.4%) patients had a delay to start adequate antimicrobial 
therapy. Only nine patients (14%) did not achieve the PD 
goal. Only two variables were independently associated with 
14-day mortality in logistic regression analysis: lack of PD goal 
(OR 9.26; 95%CI 1.50 57.17; p = 0.01) and presence of septic 
shock (OR 14.58; 95%CI 3.28-64.82; p = 0.0004). With regard to 
28-day mortality, only presence of septic shock (OR 4.90; 95% 
CI 1.36-17.62; p = 0.01 was significant. We also performed a 
subgroup analysis of predictors of 14-day mortality focused on 
patients with ESBL-producing microorganisms (30 patients). 
In this subset of patients, only the variable PD goal not 
achieved was independently associated with 14-day mortality 
(OR 13.71; 95% CI 1.38-136.21; p = 0.02).
Several factors have been demonstrated as predictors 
of mortality among patients with Enterobacteriaceae 
bacteremia, e. g. septic shock, neutropenia, higher APACHE II 
score, comorbidities, and older age.8-9 This is one of the first 
cohorts to evaluate outcomes and characteristics of patients 
with bacteremia caused by Enterobacteriaceae focused on 
characteristics of antimicrobial therapy, e.g. PD goal. 
Our study demonstrated that failure to achieve PD goal, 
as well as presence of septic shock, is associated with 
14-day mortality, but only the later variable was associated 
with 28-day mortality (Table 1). Surprisingly, the delay to 
start adequate therapy was not associated with mortality. 
Conversely, the presence of ESBLs did not impact on mortality 
rates, probably because the vast majority of patients were 
treated with carbapenems in our cohort. Interestingly, despite 
the reduced number of patients evaluated, we found that 
failure to achieve PD goal was a predictor of 14-day mortality 
among patients with infections caused by ESBL-producing 
microorganisms. This finding suggests that achievement of 
PD goal may be important among a subset of patients with 
infections caused by pathogens with higher MICs.
Carbapenems and cefepime were the only antibiotics 
utilized in our cohort. The restricted use of ceftazidime in 
recent years in our hospital by the antimicrobial management 
program and the great prevalence of ESBL may be the 
likely reason for this situation. Interestingly, we found a 
non-significant lower mortality rate among the patients who 
used meropenem (6.2%), when compared with those who used 
cefepime (37.5%) and imipenem (56.2%).
The utilization of hospital-specific susceptibility data 
(MIC) distribution provides reliable information for designing 
empirical antimicrobial dosing regimens. In recent years, the 
combination of MIC with antimicrobial drugs’ pharmacokinetic 
properties has provided clinically relevant information.3
A similar tool to analyze PD adequacy was utilized by Mohr 
et al.10 In their study, the authors analyzed 19 patients with 
serious infections and assessed the achievement of the PD goal 
which was achieved with the initial antimicrobial selection 
in only 3/19 (15.7%) patients. The authors concluded that 
standard empiric therapy is often sub-optimal. However, in 
their study the authors utilized a %T > MIC of 100 as the PD 
goal for beta-lactams. We utilized a lower PD goal in this study 
as defined elsewhere, and we found a greater achievement of 
PD goal (89%). Despite this fact, failure to achieve this PD goal 
was a predictor of mortality in our cohort.
Our study has several limitations. First, we utilized 
clearance and volume of distribution from previous population 
pharmacokinetics studies. However, since the beta-lactam 
drugs utilized had predominantly renal clearance, we think that 
those values may be suitable surrogate markers for actual beta-
lactam clearance and volume of distribution. Moreover, despite 
Variable Non-survivors  
(n = 16)
Survivors  
(n = 48)
Univariate  
p
Multivariate 
OR (95%CI) p
Age, median, SD 66 (+/-16) 63 (+/-16) 0.47 
Male sex 9 (56.2) 31 (64.6) 0.76
Comorbidities, ≥ 2 9 (56.2) 0 (62.5) 0.88
Antibiotic
Cefepime 6 (37.5) 14 (29.17) 0.62
Imipenem 9 (56.2) 27 (56.2) 0.81
Meropenem 
ICU
1 (6.2) 
15 (93.7)
7 (14.5) 
29 (60.4)
0.27 
0.02
 
4.43 (0.46-42.11) 0.19
ESBL 8 (50) 22  (45.8) 1.00
Delay to adequate treatment 
> 48h
2 (12.5) 13 (27.1) 0.39
Septic shock 10 (62.5) 5 (10.4 ) 0.0001 14.58 (3.28-64.82) 0.0004
PD goal not achieved 6 (37.5) 3 (6.2) 0.0007 9.26 (1.50-57.17) 0.01
BSI, bloodstream infection; ESBL, extended-spectrum beta-lactamase; PD, pharmacodynamics.
Table 1 - Analysis of factors associated with 14-day mortality in patients with BSI caused by Enterobacteriaceae
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the great variability of PK data among patients, we sought 
to utilize data from PK studies undertaken in hospitalized 
patients similar to our patients. Secondly, our study was 
restricted to the analysis of only three beta-lactam drugs and 
these findings cannot be extrapolated to other beta-lactams. 
Finally, the broth microdilution method, which is considered 
the gold standard microbiological method, was not employed in 
our study. 
In conclusion, our study demonstrated that failure to 
achieve a PD goal and presence of septic shock were predictors 
of 14-day mortality, but only the latter variable was predictor of 
28-day mortality among patients with bloodstream infections 
caused by Enterobacteriaceae strains. As far as we know, 
this is the first study analyzing this subject in this specific 
population. Hence, taking into account the difficulties 
in performing more accurate bedside PK/PD analysis, we 
consider our data relevant. Our results highlight the increasing 
importance of adequate PD targets in the treatment of serious 
nosocomial infections. Further well-designed studies are 
warranted to better assess this interesting subject.
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